Andrei W. Konradi - San Francisco CA Michael A. Pleiss - Sunnyvale CA Eugene D. Thorsett - Half Moon Bay CA Susan Ashwell - Plainsboro NJ Dimitrios Sarantakis - Newtown PA Gregory S. Welmaker - Jackson NJ Anthony Kreft - Langhorne PA Christopher Semko - Fremont CA Robert Warren Sullivan - Oceanside CA Christopher Joseph Soares - La Jolla CA Kiev Sui Ly - San Diego CA Christine M. Tarby - Hockessin DE
Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e. g. , human, such as asthma, Alzheimers disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
Tricyclic Compounds Useful As Hiv Reverse Transcriptase Inhibitors
Barry L. Johnson - Wilmington DE Mona Patel - Bridgewater NJ James D. Rodgers - Landenberg PA Christine M. Tarby - Hockessin DE Rajagopal Bakthavatchalam - Wilmington DE
Assignee:
Bristol-Myers Squibb Pharma Company - Princeton NJ
International Classification:
C07D47104
US Classification:
514293, 546 81
Abstract:
The present invention relates to tricyclic compounds of formula (I): or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
Diarylalkyl Cyclic Diamine Derivatives As Chemokine Receptor Antagonists
Tatsuki Shiota - Kanagawa, JP Shinsuke Yamagami - Tokyo, JP Kenichiro Kataoka - Tokyo, JP Noriaki Endo - Tokyo, JP Hiroko Tanaka - Tokyo, JP Doug Barnum - San Francisco CA Jonathan Greene - Palo Alto CA Wilna Moree - San Diego CA Michele Ramirez Weinhouse - Escondido CA Christine M. Tarby - Cardiff CA
Assignee:
Teijin Intellectual Property Center Limited - Osaka Combichem, Inc. - CA
Cyclic diamines of formula (I) or their pharmacologically acceptable acid addition salts, and their medical applications are described. These compounds inhibit the action of chemokines such as MIP-1a and/or MCP-1 on target cells, and are useful as a therapeutic drug and/or preventative drug in diseases, such as atherosclerosis, rheumatoid arthritis, and the like where blood monocytes and lymphocytes infiltrate into tissue.
Tricyclic 2-Pyrimidone Compounds Useful As Hiv Reverse Transcriptase Inhibitors
The present invention relates to tricyclic 2-pyrimidone compounds of formula (I): or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.
This invention relates to novel arylalkyl cyclic amine derivatives. This invention also relates to chemokine receptor antagonists that are be effective as therapeutic agents and/or preventive agents for diseases such as atherosclerosis, rheumatoid arthritis, transplant rejection, psoriasis, asthma, ulcerative colitis, glomerulonephritis, multiple sclerosis, pulmonary fibrosis, and myocarditis, in which tissue infiltration of blood monocytes and lymphocytes plays a major role in the initiation, progression or maintenance of the disease. Furthermore, chemokine receptor antagonists also inhibit the interaction of viruses, which attack blood monocytes and lymphocytes, through the use of a chemokine receptor. One such example is the HIV virus.
Tricyclic 2-Pyrimidone Compounds Useful As Hiv Reverse Transcriptase Inhibitors